Raptor Pharmaceutical Corp. (Nasdaq: RPTP)


The firm is investigating potential claims against the Board of Directors of Raptor Pharmaceutical Corp. ("Raptor" or "the Company") (Nasdaq- RPTP-News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Horizon Pharma plc. ("Horizon").

Under the terms of the transaction, Raptor shareholders will receive only $9.00 in cash for each share of Raptor stock they own. The investigation concerns whether the Board of Raptor breached their fiduciary duties to shareholders and whether Horizon is underpaying for the Company. The transaction may undervalue the Company and would result in a loss for many long-term Raptor shareholders. For example, the Raptor stock traded at $16.43 per share on June 22, 2015 and an analyst has set a $10.00 per share price target for Raptor stock.

If you are a current shareholder and would like to discuss your options of exercising your rights as a shareholder, which include ensuring that the company is getting the highest possible price for the company, and that the board of directors will act in the best interest of the shareholders, please contact us.

Please submit the following information so we can determine if you qualify for the suit. If you don't know all the specific details, partial information is also acceptable.

Personal Information
Name:
Phone #:
E-mail Address:
Stock Information
Do you currently own the stock? Yes   No
Purchase Date:
Quantity Purchased:
Purchase Price Per Share:

Please Note: Neither the submission to nor the receipt of information by The Law Offices of Marc S. Henzel or one of its attorneys through this website constitutes an agreement by the firm to represent the individual and does not create an attorney-client relationship.